|
**Overview**: FISH t(8;14) MYC IGH Panel**Introduction**: The FISH t(8;14) MYC IGH Panel is a diagnostic tool designed to detect t(8;14) in lymphoma using whole blood or bone marrow samples. In India, Burkitt lymphoma (BL) accounts for ~2-5 percent of non-Hodgkin lymphomas (~2,000-4,000 cases/year), with t(8;14)(q24;q32) MYC/IGH translocation present in ~80-90 percent of cases, driving MYC overexpression and aggressive behavior. High morbidity from under-testing in rural/low-SES pediatric/adult patients with rapidly growing masses, limited FISH labs, delayed intensive chemotherapy (CODOX-M/IVAC) leading to early mortality. Per hematology practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs FISH for MYC/IGH translocation over 1-2 days with high sensitivity/specificity, valuable for rapid BL confirmation and differential diagnosis from DLBCL. This diagnostic falls under genetic cancer screening and targets patients with suspected BL (jaw mass, abdominal involvement, high LDH), addressing accurate detection to guide high-intensity therapy and CNS prophylaxis. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise molecular diagnosis and improving survival. Its blood/bone marrow-based approach ensures reliable translocation detection.**Other Names**: FISH t(8;14) Pnl.**FDA Status**: FDA approved, CLIA certified for cytogenetics/oncology, compliant with 2025 standards.**Historical Milestone**: MYC/IGH FISH diagnostic for BL; in India, used in aggressive lymphoma protocols.**Purpose**: The test detects 2 parameters including MYC/IGH translocation to guide lymphoma genetic assessment, confirm BL, inform therapy.**Test Parameters**: 1. MYC/IGH Translocation, 2. Chromosomal Rearrangement.**Pretest Condition**: No fasting required; patients should have suspected Burkitt lymphoma.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for FISH).**Medical History**: Patients should provide details on mass growth, LDH, EBV status.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected t(8;14) including rapid progression, benefits of detection, and minimal discomfort from blood/bone marrow draw.**Procedural Considerations**: The test involves sample processing using FISH by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided probes/controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low tumor burden can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive MYC/IGH translocation confirms BL, necessitating specialist input. Negative may require follow-up.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: MYC IHC, karyotype for confirmation.**Test Limitations**: Detects translocation only; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Lymphoma Studies India 2023. |
